Nanoways to overcome docetaxel resistance in prostate cancer

被引：82

作者：

Ganju, Aditya ^{[1
,2
,3
]}

Yallapu, Murali M. ^{[1
,2
]}

Khan, Sheema ^{[1
,2
]}

Behrman, Stephen W. ^{[4
]}

Chauhan, Subhash C. ^{[1
,2
]}

Jaggi, Meena ^{[1
,2
]}

机构：

[1] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Coll Pharm, Memphis, TN 38163 USA

[2] Univ Tennessee, Ctr Hlth Sci, Ctr Canc Res, Coll Pharm, Memphis, TN 38163 USA

[3] Univ Tennessee, Ctr Hlth Sci, Coll Grad Hlth Sci, Memphis, TN 38163 USA

[4] Univ Tennessee, Ctr Hlth Sci, Dept Surg, Memphis, TN 38163 USA

来源：

DRUG RESISTANCE UPDATES | 2014年 / 17卷 / 1-2期

基金：

美国国家卫生研究院;

关键词：

Docetaxel; Chemoresistance; Nanotechnology; Nanomedicine; Nanoparticles; Drug delivery; Drug targeting; Prostate cancer; POLY(BETA-AMINO ESTER) NANOPARTICLES; LOADED MAGNETIC NANOPARTICLES; TUMOR-TARGETED DELIVERY; PH-SENSITIVE SYSTEM; RANDOMIZED PHASE-II; IN-VITRO; MULTIDRUG-RESISTANCE; CO-DELIVERY; THERAPEUTIC-EFFICACY; GOLD NANOPARTICLES;

D O I：

10.1016/j.drup.2014.04.001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Prostate cancer is the most common non-cutaneous malignancy in American men. Docetaxel is a useful chemotherapeutic agent for prostate cancer that has been available for over a decade, but the length of the treatment and systemic side effects hamper compliance. Additionally, docetaxel resistance invariably emerges, leading to disease relapse. Docetaxel resistance is either intrinsic or acquired by adopting various mechanisms that are highly associated with genetic alterations, decreased influx and increased efflux of drugs. Several combination therapies and small P-glycoprotein inhibitors have been proposed to improve the therapeutic potential of docetaxel in prostate cancer. Novel therapeutic strategies that may allow reversal of docetaxel resistance include alterations of enzymes, improving drug uptake and enhancement of apoptosis. In this review, we provide the most current docetaxel reversal approaches utilizing nanotechnology. Nanotechnology mediated docetaxel delivery is superior to existing therapeutic strategies and a more effective method to induce P-glycoprotein inhibition, enhance cellular uptake, maintain sustained drug release, and improve bioavailability. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：13 / 23

页数：11

共 115 条

[1] Advances in Androgen Receptor Targeted Therapy for Prostate Cancer [J].

Ahmed, Alia ;

Ali, Shadan ;

Sarkar, Fazlul H. .

JOURNAL OF CELLULAR PHYSIOLOGY, 2014, 229 (03) :271-276

[2]

Al Ekish S, 2013, JSLS-J SOC LAPAROEND, V17, P423, DOI 10.4293/108680813X13693422518551

[3] Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer [J].

Aparicio, Ana M. ;

Harzstark, Andrea L. ;

Corn, Paul G. ;

Wen, Sijin ;

Araujo, John C. ;

Tu, Shi-Ming ;

Pagliaro, Lance C. ;

Kim, Jeri ;

Millikan, Randall E. ;

Ryan, Charles ;

Tannir, Nizar M. ;

Zurita, Amado J. ;

Mathew, Paul ;

Arap, Wadih ;

Troncoso, Patricia ;

Thall, Peter F. ;

Logothetis, Christopher J. .

CLINICAL CANCER RESEARCH, 2013, 19 (13) :3621-3630

[4] Intrinsic therapeutic applications of noble metal nanoparticles: past, present and future [J].

Arvizo, Rochelle R. ;

Bhattacharyya, Sanjib ;

Kudgus, Rachel A. ;

Giri, Karuna ;

Bhattacharya, Resham ;

Mukherjee, Priyabrata .

CHEMICAL SOCIETY REVIEWS, 2012, 41 (07) :2943-2970

[5] Modulating Pharmacokinetics, Tumor Uptake and Biodistribution by Engineered Nanoparticles [J].

Arvizo, Rochelle R. ;

Miranda, Oscar R. ;

Moyano, Daniel F. ;

Walden, Chad A. ;

Giri, Karuna ;

Bhattacharya, Resham ;

Robertson, J. David ;

Rotello, Vincent M. ;

Reid, Joel M. ;

Mukherjee, Priyabrata .

PLOS ONE, 2011, 6 (09)

[6] Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents [J].

Bahl, Amit ;

Masson, Susan ;

Birtle, Alison ;

Chowdhury, Simon ;

de Bono, Johann .

CANCER TREATMENT REVIEWS, 2014, 40 (01) :170-177

[7] Downregulation of miR-205 and miR-31 confers resistance to chemotherapy-induced apoptosis in prostate cancer cells [J].

Bhatnagar, N. ;

Li, X. ;

Padi, S. K. R. ;

Zhang, Q. ;

Tang, M-S ;

Guo, B. .

CELL DEATH & DISEASE, 2010, 1 :e105-e105

[8] Efficient Delivery of Gold Nanoparticles by Dual Receptor Targeting [J].

Bhattacharyya, Sanjib ;

Khan, Jameel Ahmad ;

Curran, Geoffry L. ;

Robertson, J. David ;

Bhattacharya, Resham ;

Mukherjee, Priyabrata .

ADVANCED MATERIALS, 2011, 23 (43) :5034-5038

[9] Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy [J].

Chu, Kevin S. ;

Schorzman, Allison N. ;

Finniss, Mathew C. ;

Bowerman, Charles J. ;

Peng, Lei ;

Luft, James C. ;

Madden, Andrew J. ;

Wang, Andrew Z. ;

Zamboni, William C. ;

DeSimone, Joseph M. .

BIOMATERIALS, 2013, 34 (33) :8424-8429

[10] Clinical pharmacokinetics of docetaxel [J].

Clarke, SJ ;

Rivory, LP .

CLINICAL PHARMACOKINETICS, 1999, 36 (02) :99-114

← 1 2 3 4 5 6 7 8 9 10 →